Organization
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II
2 abstracts
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.Org: Saint-Louis Hospital, APHP, University Paris Cité, Paris and Saint Cloud, France,